279 related articles for article (PubMed ID: 26873871)
21. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
[TBL] [Abstract][Full Text] [Related]
22. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Blonde L; Klein EJ; Han J; Zhang B; Mac SM; Poon TH; Taylor KL; Trautmann ME; Kim DD; Kendall DM
Diabetes Obes Metab; 2006 Jul; 8(4):436-47. PubMed ID: 16776751
[TBL] [Abstract][Full Text] [Related]
23. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
Viswanathan P; Chaudhuri A; Bhatia R; Al-Atrash F; Mohanty P; Dandona P
Endocr Pract; 2007 Sep; 13(5):444-50. PubMed ID: 17872344
[TBL] [Abstract][Full Text] [Related]
24. Leptin restores the insulinotropic effect of exenatide in a mouse model of type 2 diabetes with increased adiposity induced by streptozotocin and high-fat diet.
Sakai T; Kusakabe T; Ebihara K; Aotani D; Yamamoto-Kataoka S; Zhao M; Gumbilai VM; Ebihara C; Aizawa-Abe M; Yamamoto Y; Noguchi M; Fujikura J; Hosoda K; Inagaki N; Nakao K
Am J Physiol Endocrinol Metab; 2014 Oct; 307(8):E712-9. PubMed ID: 25159327
[TBL] [Abstract][Full Text] [Related]
25. Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
Horowitz M; Aroda VR; Han J; Hardy E; Rayner CK
Diabetes Obes Metab; 2017 May; 19(5):672-681. PubMed ID: 28058769
[TBL] [Abstract][Full Text] [Related]
26. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.
Jaiswal M; Martin CL; Brown MB; Callaghan B; Albers JW; Feldman EL; Pop-Busui R
J Diabetes Complications; 2015; 29(8):1287-94. PubMed ID: 26264399
[TBL] [Abstract][Full Text] [Related]
27. Exenatide versus glibenclamide in patients with diabetes.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Diabetes Technol Ther; 2010 Mar; 12(3):233-40. PubMed ID: 20151774
[TBL] [Abstract][Full Text] [Related]
28. Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial.
Shi L; Zhu J; Yang P; Tang X; Yu W; Pan C; Shen M; Zhu D; Cheng J; Ye X
Obes Res Clin Pract; 2017; 11(5):607-615. PubMed ID: 28161303
[TBL] [Abstract][Full Text] [Related]
29. Summaries for patients. Exenatide therapy for type 2 diabetes.
Ann Intern Med; 2007 Apr; 146(7):I18. PubMed ID: 17404346
[No Abstract] [Full Text] [Related]
30. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Buse JB; Bergenstal RM; Glass LC; Heilmann CR; Lewis MS; Kwan AY; Hoogwerf BJ; Rosenstock J
Ann Intern Med; 2011 Jan; 154(2):103-12. PubMed ID: 21138825
[TBL] [Abstract][Full Text] [Related]
31. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial.
Abdul-Ghani MA; Puckett C; Triplitt C; Maggs D; Adams J; Cersosimo E; DeFronzo RA
Diabetes Obes Metab; 2015 Mar; 17(3):268-75. PubMed ID: 25425451
[TBL] [Abstract][Full Text] [Related]
32. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
[TBL] [Abstract][Full Text] [Related]
33. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.
King AB; Montanya E; Pratley RE; Blonde L; Svendsen CB; Donsmark M; Sesti G
Endocr Pract; 2013; 19(1):64-72. PubMed ID: 23186975
[TBL] [Abstract][Full Text] [Related]
34. Psychological and quality of life changes in patients using GLP-1 analogues.
Grant P; Lipscomb D; Quin J
J Diabetes Complications; 2011; 25(4):244-6. PubMed ID: 21601480
[TBL] [Abstract][Full Text] [Related]
35. [Type 2 diabetic patient with reduced beta-cell function. New substance class: incretin-mimetics].
MMW Fortschr Med; 2005 Aug; 147(31-32):55. PubMed ID: 16128203
[No Abstract] [Full Text] [Related]
36. [Exenatide convinces in a six-month study: HbA1c sunk significantly].
MMW Fortschr Med; 2009 May; 151(19):51. PubMed ID: 19827448
[No Abstract] [Full Text] [Related]
37. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
[No Abstract] [Full Text] [Related]
38. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Montilla S; Marchesini G; Sammarco A; Trotta MP; Siviero PD; Tomino C; Melchiorri D; Pani L;
Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1346-53. PubMed ID: 25300980
[TBL] [Abstract][Full Text] [Related]
39. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
[TBL] [Abstract][Full Text] [Related]
40. Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus.
Su K; Lv C; Ji Z; Wang Y; Wang H; Bai Y; Liu Y
Am J Ther; 2018; 25(6):e609-e616. PubMed ID: 26844723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
